Hook & thesis
TG Therapeutics (TGTX) is a buy here. The market is finally giving the company credit for commercial traction in multiple sclerosis with BRIUMVI and for management's explicit push to expand the drug's reach and dosing formats. Management has repeatedly raised guidance after strong quarterly prints in 2025 and early signals pointing to a stronger 2026 outlook have the stock sitting at a constructive entry point.
My thesis: BRIUMVI's commercial momentum plus continued label/route-of-administration expansion can support a re-rating from current multiples. With the shares trading near $39.21 and a market cap around $6.0 billion, the risk/reward favors buying into steady execution now with a disciplined stop and targets tied to multiple-expansion and continued top-line acceleration.
What the company does and why the market should care
TG Therapeutics is focused on treatments for B-cell malignancies and autoimmune diseases; its commercial story today is centered on BRIUMVI, an FDA- and European-approved therapy for multiple sclerosis. The levers that matter for investors are (1) continued growth of BRIUMVI U.S. net sales as the field uptake broadens; (2) expansion into new dosing regimens and subcutaneous delivery to improve convenience and retention; and (3) potential label and indication extensions that materially expand the addressable market.
Why the market should care: MS is a large, underpenetrated specialty market where durable efficacy, safety, and differentiated delivery can win sustainable share. TG has translated its R&D efforts into commercial revenues already, and recent guidance lifts suggest management is confident in execution.
Supporting numbers
- Market cap: roughly $6.0 billion ($6,002,423,640 snapshot).
- Latest reported commercial traction: Q1 2025 U.S. net sales for BRIUMVI were $119.7 million; Q2 2025 revenue growth accelerated with a reported 91% increase, and management raised full-year revenue guidance to $585 million in 2025.
- Profitability and valuation: reported EPS stands at about $3.02, implying a trailing P/E near 13x (ratios show ~12.99 to 13.66 depending on the series). ROE is unusually high at ~79% and return on assets about 30%, both signaling strong operating leverage on current sales.
- Balance sheet metrics: enterprise value is about $6.30 billion with EV/Sales around 9 and EV/EBITDA ~42. Management carries some leverage - debt-to-equity is 1.28 - and the reported cash metric shows $2.36 (as presented in the latest ratios).
- Liquidity & market activity: float ~142.0M shares, shares outstanding ~153.1M, average volume in the recent windows ranges from ~1.48M to ~2.19M, but short interest is meaningful (roughly 28M shares at mid-May settlement, days-to-cover above 10), which can amplify moves on news.
Valuation framing
At a market cap near $6.0 billion and EPS around $3.02, the stock trades in the low-to-mid teens on a P/E basis. That is not an aggressive valuation for a growing specialty pharma name that is already generating meaningful revenue. EV/Sales near 9 and EV/EBITDA above 40 reflect a market that still prices in a substantial growth premium and execution risk. Put simply, the stock sits between outright growth multiples and value metrics: enough upside exists via continued top-line acceleration, margin improvement, and multiple expansion if management hits or exceeds its upgraded 2026 outlook.
Qualitatively, this setup resembles a commercialization re-rating more than a speculative binary biotech bet: revenues are real, margins can expand with scale, and the company has a concrete plan to broaden BRIUMVI's use (including subcutaneous formulations and exploration into progressive MS per investor communications).
Catalysts to watch (2-5)
- Management updates on 2026 guidance - confirmation of stronger revenue trajectory or incremental margin assumptions would be a direct catalyst to re-rating.
- Commercial milestones for subcutaneous BRIUMVI or new dosing regimens - better convenience often translates to faster adoption and longer patient retention.
- New indication or label expansion data - early positive readouts or regulatory signals for broader MS populations would materially increase the addressable market.
- Partnerships or high-profile awareness campaigns - initiatives that demonstrably grow patient starts (for example, awareness collaborations) can accelerate adoption.
Actionable trade plan
Entry, stop, and target are defined with explicit horizons. I label the trade as long with the following structure:
- Entry: Buy at $39.21 (current market).
- Stop loss: $33.00. This level sits below near-term price support and limits downside to a manageable level if commercial momentum stalls or guidance disappoints.
- Target: $54.00. This target implies a P/E in the high-teens on current EPS and reflects a reasonable multiple expansion combined with revenue and margin improvements over the next several quarters.
Horizon and rationale:
- Short term (10 trading days): Look for an initial run toward $44.00 if the next management update includes incremental detail on 2026 guidance or a positive commercial readout. This is a near-term trade to capture immediate sentiment-driven moves.
- Mid term (45 trading days): Expect movement toward $48.00 on sustained uptake or expanded access announcements. The mid-term keeps enough time for commercial cadence to show in weekly patient-start metrics or early sales updates.
- Long term (180 trading days): Hold up to 180 trading days for the full thesis to play out toward the $54.00 target if management confirms an upgraded multi-quarter outlook, subcutaneous progress, or additional label wins. The longer tenor allows revenue recognition and margin expansion to drive valuation.
Position sizing & risk management
Because short-interest and days-to-cover remain elevated, size the position conservatively relative to portfolio volatility (suggest 2-4% of portfolio value on entry). Use the $33 stop and consider trimming into strength: take partial profits at the mid-term $48 level and let the remainder run to $54.
Risks and counterarguments
Below are the principal risks to this trade, and one counterargument to the bullish thesis.
- Commercial execution miss: If BRIUMVI starts to lose share, or patient starts slow relative to expectations, revenue and margin dynamics could disappoint and compress multiples quickly.
- Regulatory / label risk: While BRIUMVI is approved, any negative regulatory ruling around new dosing or safety signals would be damaging given the current reliance on expansion for growth.
- High short interest and potential volatility: ~28M shares short creates two-way risk - sharp squeezes can overshoot on the upside, but concentrated short positioning also magnifies downside when sentiment turns.
- Leverage and capital structure: Debt-to-equity is ~1.28. If free cash flow remains negative (the recent free cash flow line showed negative FCF), the company may need to access capital markets under unfavorable conditions, diluting equity value.
- Valuation sensitivity: EV/Sales of ~9 and EV/EBITDA north of 40 embed strong growth expectations; a single quarter of shortfall in revenues or margins could lead to meaningful multiple contraction.
Counterargument: One could reasonably argue TGTX is already priced for perfection. The current multiples assume continued rapid uptake, margin expansion, and successful expansion into new dosing/indication areas. If any of these assumptions prove optimistic - for example, if subcutaneous progress slows or competitive entrants pressure pricing/share - the company could revert to a lower multiple and the trade would fail even if BRIUMVI remains a solid product.
What would change my mind
I would downgrade from a strong-buy if management issues guidance that falls short of street expectations or if we see clear signs of slowing patient starts for BRIUMVI despite broader awareness efforts. Conversely, a sustained string of beats to guidance, formal approval or a regulatory green light for subcutaneous BRIUMVI, or demonstrable expansion into a progressive MS population would strengthen the bull case and warrant adding to the position.
Conclusion
TG Therapeutics represents a pragmatic, risk-managed long opportunity. The company has transitioned from development to commercial execution, the market cap and P/E leave room for multiple expansion if BRIUMVI continues to grow, and management has shown a willingness to raise guidance when warranted. Buy at $39.21 with a $33 stop and a first upside target near $54.00, monitoring commercial cadence and management guidance as primary catalysts. Size the position modestly and scale out in stages to manage the elevated volatility that comes from significant short interest.
Key metrics recap
- Current price: $39.21
- Market cap: ~$6.0 billion
- EPS: ~$3.02; trailing P/E ~13x
- Q1 2025 BRIUMVI U.S. net sales: $119.7 million; Q2 2025 revenue growth reported at 91%; 2025 guidance raised to $585 million
- Entry: $39.21 | Stop: $33.00 | Target: $54.00